RadiaDyne Announces First Commercial Sale Milestone Of Their OARtrac Patient Dose Monitoring System To Leading Cancer Center

Tuesday, January 30, 2018 Cancer News
Email Print This Page Comment bookmark
Font : A-A+

HOUSTON, Jan. 30, 2018 /PRNewswire/ -- RadiaDyne announces the first commercial sale in New York

City, New York of their upcoming OARtrac system to one of the recognized leaders in radiation delivery for cancer treatment.  "We are excited about the early interest and momentum of this new technology, and the
industry's recognition of the OARtrac system's capabilities to provide the best clinical solution for monitoring treatment dose," said Bret Boudousquie, RadiaDyne's President.  "These early clinical adopters are leading the way for other centers seeking innovative technology for improved outcomes in cancer treatment. It is exciting to see early orders even prior to the official clinical launch of the technology," said John Isham, RadiaDyne's Founder and CEO. 

ABOUT THE OARTRAC PLATFORM. OARtrac® is the first of its kind patient radiation dose monitoring system which provides gold standard accuracy, real-time pinpoint measurement, and proprietary intracavitary delivery devices to physically measure radiation dose during photon external beam therapy and HDR brachytherapy radiation treatments. OARtrac® provides critical radiation dose feedback which helps facilitate adaptive radiotherapy for true personalized treatment with the goal to reduce side effects and offer better clinical outcomes.

ABOUT RADIADYNE:  RadiaDyne is a privately held medical diagnostic and device company focused on patient dose monitoring technology to improve cancer treatment outcomes.  RadiaDyne designs and innovates specialized sensor technology and treatment devices which assist Radiation Oncologists in delivering radiation dose to the cancerous targets, while minimizing damage to the surrounding healthy tissue.  RadiaDyne is the pioneer in developing and offering real-time patient dose monitoring systems through their patented OARtrac® system.

 

Cision View original content:http://www.prnewswire.com/news-releases/radiadyne-announces-first-commercial-sale-milestone-of-their-oartrac-patient-dose-monitoring-system-to-leading-cancer-center-300590239.html

SOURCE RadiaDyne



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store